



Biotech Daily

Thursday January 20, 2022

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: AMPLIA UP 6%; RESONANCE DOWN 10.5%**
- * **RESAPP SIGNS PHILIPPINES HOMIFY FOR RESAPDX TELEHEALTH**
- * **ALTHEA H1 MARIJUANA RECEIPTS UP 111% TO \$9.9m**
- * **STARPHARMA RECEIVES \$7.7m FEDERAL R&D TAX INCENTIVE**
- * **EMYRIA READIES FOR O-T-C EMD-RX5 MARIJUANA CAPSULE TRIAL**
- * **IMEX: THAILAND APPROVES AQUILA, 1st SALE; BJC DISTRIBUTOR**
- * **VGI: AMAZON TO STOCK NE1-ELITE, NE1-HEART THROUGH**
- * **TELIX REQUESTS CAPITAL RAISING TRADING HALT**
- * **AROVELLA REQUESTS CAPITAL RAISING TRADING HALT**
- * **HERAMED TAKES CAPITAL RAISING HALT TO SUSPENSION**
- * **MEDIBIO: CPS UNDERWRITES \$1m OF \$3.4m RIGHTS OFFER**
- * **CANN GROUP: RUA INVESTORS APPROVE ZALM ACQUISITION**
- * **OPTISCAN LOSES DIRECTOR DR PHIL CURRIE**

MARKET REPORT

The Australian stock market was up 0.13 percent on Thursday January 20, 2022, with the ASX200 up 9.9 points to 7,342.4 points. Eighteen of the Biotech Daily Top 40 stocks were up, 11 fell, 10 traded unchanged and one was untraded.

Amplia was the best, up one cent or 6.1 percent to 17.5 cents, with 282,002 shares traded. Patrys climbed 5.4 percent; Actinogen and Cynata were up more than three percent; Impedimed, Medical Developments, Opthea and Paradigm rose more than two percent; Clinuvel, Orthocell, Polynovo, Universal Biosensors and Volpara were up one percent or more; with CSL, Emvision, Genetic Signatures, Kazia, Nanosonics, Pro Medicus and Resmed up by less than one percent.

Resonance led the falls, down two cents or 10.5 percent to 17 cents, with 224,686 shares traded. Atomo, Proteomics and Uscom fell more than four percent; Avita was down three percent; Antisense shed 2.7 percent; Alcidion, Mesoblast, Oncosil and Starpharma lost more than one percent; with Cochlear and Next Science down less than one percent.

RESAPP HEALTH

Resapp says it has a non-exclusive, three-year binding letter-of-intent with the Manila, Philippines-based Homify Corp, integrating Resappdx into its telehealth services. Resapp said that its Resappdx respiratory disease diagnostic would be “the foundational technology” on Homify’s telehealth product, pending approval as a medical device in the Philippines.

The company said that Homify planned to integrate Resappdx into its systems and launch by “the middle of this calendar year”.

Resapp said that the letter-of-intent specified undisclosed pricing on a monthly subscription basis, tiered by the number of tests performed each month.

Resapp was unchanged at six cents.

ALTHEA

Althea says customer receipts for the six months to December 30, 2021, was \$9,896,000 compared to \$4,696,000 for the six months to December 31, 2020.

Althea said that for the three months to December 31, receipts from sales of recreational marijuana in Canada amounted to \$2.7 million, with record sales of “pharmaceutical Cannabis” in the UK of \$2.8 million.

The company said it a cash burn of \$2,177,000 for the three months to December 31, with cash and equivalents of \$10,254,000 at December 31, 2021, compared to \$8,967,000 at December 31, 2020.

Althea was up 2.5 cents or 11.9 percent to 23.5 cents.

STARPHARMA

Starpharma says it has received \$7,747,601 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Starpharma said the rebate related to research and development expenditure for the year to June 30, 2021.

Starpharma fell 1.5 cents or 1.3 percent to \$1.145.

EMYRIA

Emyria says it expects a phase I trial of its over-the-counter EMD-RX5 cannabidiol capsule for psychological distress and irritable bowel syndrome to begin by April.

Emyria said that Adelaide’s CMax Clinical Research would conduct the safety and bioavailability trial’s two programs comparing low-dose EMD-RX5 to Epidyolex, which it said was the only cannabidiol-based drug approved by the Australian Therapeutic Goods Administration and the US Food and Drug Administration.

The company said the EMD-003 program would compare the two drugs for temporary symptoms of psychological distress, with the EMD-004 program comparing for symptoms associated with irritable bowel syndrome.

Emyria said that good manufacturing process production of EMD-RX5 had begun.

The company said it would begin a pivotal phase III trial following the conclusion of the phase I trial, and was aiming for its first submission to the TGA by the end of the year.

Emyria was up half a cent or 1.1 percent to 44.5 cents.

IMEX HEALTH SERVICES

Imex says it has sold its first Aquila in the Cloud radiology workflow management platform in Thailand to Siriraj Hospital and appointed BJC Healthcare its distributor.

Imex said that it had approval from the Thailand Food and Drug Administration for the picture archiving and communications system (PACS) imaging software.

The company said the contract with Bangkok's Siriraj Hospital Mobile Stroke Unit would be volume based and billed in US dollars, but did not state a contract value.

Imex said it had an international distribution agreement for its software with the Bangkok-based Berli Jucker Public Co (BJC) through BJC Healthcare Co.

Imex was up two cents or two percent to \$1.00.

VGI HEALTH TECHNOLOGY

VGI says its Hialeah, Florida-based subsidiary Invictus Nutraceuticals will sell its NE1-Elite and NE1-Heart vitamin E derivative food additives through the Amazon platform.

VGI said NE-1 Elite was designed to reduce delayed onset muscle soreness and improve recovery after long workouts and NE1-Heart was designed to improve heart health and antioxidant status in the body.

The company said both were designed to improve the bioavailability and efficacy of tocotrienols, a natural vitamin E derivative.

VGI said Invictus would begin marketing of the products on Amazon "in the near future".

On the National Stock Exchange VGI was untraded at 25 cents.

TELIX PHARMACEUTICALS

Telix has requested a trading halt pending an announcement "regarding a material capital raise".

Trading will resume on January 24, 2022 or on an earlier announcement.

Telix last traded at \$8.09.

AROVELLA THERAPEUTICS (FORMERLY SUDA PHARMACEUTICALS)

Arovella has requested a trading halt "pending an announcement regarding a proposed capital raising, including a share placement."

Trading will resume on January 24, 2022 or on an earlier announcement.

Arovella last traded at 3.9 cents.

HERAMED

Heramed has requested a voluntary suspension to follow its January 18, 2022 trading halt pending an "commercial licence agreement" for Heracare (BD: Jan 18, 2022).

The company said it expected the suspension to last until January 21, 2022 or on the release of an earlier announcement.

Heramed last traded at 29 cents.

MEDIBIO

Medibio says the Perth-based CPS Capital Group will underwrite up to \$1 million of its non-renounceable entitlement offer which hopes to raise \$3.4 million.

In December, Medibio said it hoped to raise \$5.65 million through a \$2.25 million placement at 0.5 cents a share and a \$3.4 million one-for-three rights offer at the same price, but underwriting terms were “yet to be finalized” (BD: Dec 15, 2021). Today, the company said that CPS would have the right to place any shortfall for three months after the close of the offer, and would “receive an underwriting fee of \$20,000 and a six percent fee for the underwriting amount being \$1 million”. Medibio fell 0.1 cents or 20 percent to 0.4 cents.

CANN GROUP

Cann Group says New Zealand's Rua Biosciences has approved the proposed acquisition of Auckland's Zalm Therapeutics, of which Cann owns 8.36 percent. In November, Cann Group said it would sell its interest in Zalm Therapeutics to the Rua marijuana company for scrip (BD: Nov 30, 2021). Today, Cann Group said Rua shareholders voted to approve the proposal. Cann Group was unchanged at 28.5 cents.

OPTISCAN IMAGING LIMITED

In Optiscan chair Robert Cooke's address to the annual general meeting the company said that Dr Phil Currie would resign as a director following the meeting. In 2017, Optiscan said it had appointed Dr Currie as a director (BD: Jul 17, 2017). Optiscan was up one cent or 5.9 percent to 18 cents.

**Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053
email: editor@biotechdaily.com.au; www.biotechdaily.com.au; twitter: @biotech_daily**